Shares of Pain Therapeutics have been lopped in half as Big Pharma partner Pfizer has put Pain's Remoxy, its lead drug candidate, under review. Durect has plunged more than 35%, as its extended-release tech is used in the product.
In this video, health-care analyst David Williamson picks up the pieces for investors and takes a closer look at the abuse-resistant painkiller space while discussing the future of Pain Therapeutics.
Obamacare will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more.